| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.1K | 5.6% | 7.9% |
| Total Income | 1.1K | 5.6% | 7.9% |
| Expenditure | 1.1K | 37.1% | 36.1% |
| PBT | -48.40 | 125.2% | 133.5% |
| Net Profit | -77.90 | 159.6% | 188.8% |
| OPM | -2.87% | 23.64pp | 21.30pp |
| NPM | -7.20% | 19.98pp | 15.95pp |
| EPS | -0.40 | 159.7% | 190.9% |
CooperCompanies Announces Second Quarter 2026 Results
05 Jun 2026 · 5 Jun, 2:01 am
Summary
CooperCompanies reported second quarter 2026 revenue of $1.082 billion, an 8% increase year-over-year, with organic growth of 5%. Non-GAAP diluted EPS rose 26% to $1.21, driven by solid execution across both CooperVision and CooperSurgical segments. The company has reached agreements to resolve substantially all claims related to a CooperSurgical product recall, marking a significant step in addressing the issue. Management updated its fiscal year 2026 guidance, expecting total revenue between $4.285 billion and $4.321 billion and non-GAAP diluted EPS between $4.58 and $4.66.
Key Highlights
- 1
Second quarter 2026 revenue was $1.082 billion, an increase of 8% from the prior year's second quarter.
- 2
Second quarter 2026 Non-GAAP diluted EPS was $1.21, up $0.25 or 26% compared to last year's second quarter.
- 3
CooperVision revenue increased 8% year-over-year to $723.5 million in the second quarter of 2026.
- 4
CooperSurgical revenue grew 8% year-over-year to $358.0 million in the second quarter of 2026.
- 5
The Company updated its fiscal year 2026 financial guidance, projecting total revenue between $4.285 billion and $4.321 billion.
- 6
Fiscal 2026 non-GAAP diluted EPS guidance is projected to be between $4.58 and $4.66.
Management Comments
Al White
We delivered a strong second quarter, achieving record revenue and non-GAAP earnings per share while marking our tenth consecutive quarter of exceeding consensus earnings expectations. Our performance reflects solid execution across our businesses, supported by new product launches, favorable demand drivers, and ongoing focus on operational discipline. In addition, we have reached agreements to resolve substantially all of the outstanding claims related to CooperSurgical's fertility media recall, representing an important step in addressing this issue and allowing us to move forward with our strategic review. Moving forward, we are focused on driving sustainable, profitable growth and strong cash flow, while maintaining discipline in a dynamic operating environment.
Informational and educational content only. Not investment advice.